ONCOSIL MEDICAL ORDINARY (OSL) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXOSPREY Registry Abstract Accepted for EANM 2026 Congress
other announcement
KalkineOncoSil Medical Expands Local Manufacturing for the Next Phase of Growth
Highlights Local manufacturing capability reaches a major milestone. Validation strengthens production quality and supply confidence. Commercial rollout moves closer with regulatory progress. OncoSil Medical has completed an important manufacturing validation milestone, reinforcing its local production capabilities and supporting its broader commercial expansion strategy. The development is expected to strengthen operational efficiency, supply reliability,...
Small CapsOncoSil Medical Completes Manufacturing Validation
other announcement
OncoSil Medical files for FDA approval of bile duct cancer device in major US milestone
Sydney-based medical device company OncoSil Medical (ASX: OSL) has completed the submission of its Humanitarian Device Exemption (HDE) application to the US Food and Drug Administration (FDA) for its OncoSil device for the treatment of distal cholangiocarcinoma, a form of bile duct cancer. The FDA is expected to complete its review within 45 da...
OncoSil Selected for Major European Pancreatic Cancer Study
other announcement
TRIPP-FFX Abstract Published on ESMO GI 2026 Website
other announcement
Google NewsBiotech Back in Play? Why OncoSil Medical (ASX: OSL) Is Turning Heads on the ASX - Kalkine
Biotech Back in Play? Why OncoSil Medical (ASX: OSL) Is Turning Heads on the ASX Kalkine
OncoSil Medical (ASX:OSL) Spikes as Biotech Traders Eye a Turnaround - Kalkine
OncoSil Medical (ASX:OSL) Spikes as Biotech Traders Eye a Turnaround Kalkine
OncoSil Medical (ASX:OSL): Cancer-Treatment Stock Jumps as Biotech Traders Return - Kalkine
OncoSil Medical (ASX:OSL): Cancer-Treatment Stock Jumps as Biotech Traders Return Kalkine
Why OncoSil’s Quiet Update Could Signal a Defining Period Ahead
Highlights OncoSil Medical highlighted a potentially milestone-rich second half of the year following recent regulatory and clinical progress. Key areas of focus include US regulatory advancement, clinical trial outcomes, and manufacturing expansion. Commercial adoption remains the most important measure of long-term success despite recent achievements. OncoSil enters a crucial phase as regulatory progress, clinical data, manufacturing expansion, and commercial adoption become the central the...
OncoSil Medical (ASX:OSL) flags a catalyst-heavy back half of 2026 - Stocks Down Under
OncoSil Medical (ASX:OSL) flags a catalyst-heavy back half of 2026 Stocks Down Under
Publication verifies OncoSil strong localisation in pancreas
other announcement
TRIPP FFX accepted for oral presentation at ESMO GI 2026
other announcement
TRIPP-FFX Clinical Trial Meets Co-Primary Endpoints
other announcement
OncoSil Medical (ASX:OSL) Slides as Investors Reassess Healthcare Micro-Cap - Kalkine
OncoSil Medical (ASX:OSL) Slides as Investors Reassess Healthcare Micro-Cap Kalkine
TRIPP FFX Clinical Trial to Report Results in June
other announcement
Key New Ethics Approval for Italian Patient Registry
other announcement
Notification regarding unquoted securities - OSL
other announcement
New Clinical Evidence for OncoSil Device Presented at ASCO
other announcement
OncoSil Medical (ASX:OSL) Shares Skyrocket ~54% Today- Here's Why? - Kalkine
OncoSil Medical (ASX:OSL) Shares Skyrocket ~54% Today- Here's Why? Kalkine
OncoSil Medical Receives TGA Approval in Australia
other announcement
OncoSil Medical Insiders Lose Out As Stock Sinks To AU$0.45 - simplywall.st
OncoSil Medical Insiders Lose Out As Stock Sinks To AU$0.45 simplywall.st
OSPREY Interim Results Presented at ESGE Days 2026
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
OSPREY Registry Data Accepted for Presentation at ESGE Days
other announcement
Change of Director's Interest Notice X2
director_dealing announcement
Security Class Reinstatement to Quotation - OSLOE
other announcement
Top 20 Holders and Range of Units for Attaching Options
other announcement
Notice of Extraordinary General Meeting/Proxy Form
other announcement